AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-21. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Protein structure is the three-dimensional arrangement of atoms in an amino acid-chain molecule. Proteins are polymers – specifically polypeptides – formed from sequences of amino acids, which are the monomers of the polymer. A single amino acid monomer may also be called a residue, which indicates a repeating unit of a polymer. Proteins form by amino acids undergoing condensation reactions, in which the amino acids lose one water molecule per reaction in order to attach to one another with a peptide bond. By convention, a chain under 30 amino acids is often identified as a peptide, rather than a protein. To be able to perform their biological function, proteins fold into one or more specific spatial conformations driven by a number of non-covalent interactions, such as hydrogen bonding, ionic interactions, Van der Waals forces, and hydrophobic packing. To understand the functions of proteins at a molecular level, it is often necessary to determine their three-dimensional structure. This is the topic of the scientific field of structural biology, which employs techniques such as X-ray crystallography, NMR spectroscopy, cryo-electron microscopy (cryo-EM) and dual polarisation interferometry, to determine the structure of proteins. Protein structures range in size from tens to several thousand amino acids. By physical size, proteins are classified as nanoparticles, between 1–100 nm. Very large protein complexes can be formed from protein subunits. For example, many thousands of actin molecules assemble into a microfilament.
=== POMC === POMC produced from the melanotropes of the pars intermedia is cleaved into adrenocorticotropic hormone (ACTH) and β-lipotropin (β-LPH). The majority of ACTH is then cleaved into α-MSH and corticotropin-like intermediate peptide (CLIP). CLIP is thought to have an influence on subsequent insulin resistance that can be seen in PPID horses. ACTH is also produced by corticotropes in the pars distalis of the equine pituitary. In a normal horse, this accounts for the majority of ACTH production. ACTH produced by the pars distalis is subject to negative feedback in a normal horse, so high cortisol levels reduce ACTH production by the pituitary, subsequently reducing cortisol levels. In a horse with PPID, ACTH levels are high as a result of pars intermedia production, but it is not subject to negative feedback regulation. Despite the high levels of ACTH, cortisol levels vary, and are sometimes lower than normal. Additionally, hyperplasia of the adrenal cortex is infrequent. The role of ACTH is, therefore, still poorly understood.
Durham County Council is the local authority for the unitary authority area of County Durham in North East England. The unitary authority area is smaller than the ceremonial county of Durham, which additionally includes Darlington, Hartlepool, and part of Stockton-on-Tees. The council has its headquarters at County Hall in the city of Durham, and consists of 98 councillors. It is a member of the North East Combined Authority. Since the 2025 Durham County Council election the council has been under the majority control of Reform UK. The chair of the council is Robbie Rodis, and the leader is Andrew Husband. The council had a Labour Party majority from 1925 until 2021, when it fell into no overall control. Between 1889 and 1974 Durham consisted of an administrative county governed by a county council, and several county boroughs with their own councils. In 1974, as part of reforms to local government in England, Durham was reconstituted as a two-tier non-metropolitan county governed by a county council and eight district councils. In 1997, the Borough of Darlington was reconstituted as a unitary authority, making it independent of the county council. Durham County Council was itself reconstituted as a unitary authority in 2009, when the seven remaining district councils were abolished and the county council took on their responsibilities.
The prostate is an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. It is found in all male mammals. It differs between species anatomically, chemically, and physiologically. Anatomically, the prostate is found below the bladder, with the urethra passing through it. It is described in gross anatomy as consisting of lobes and in microanatomy by zone. It is surrounded by an elastic, fibromuscular capsule and contains glandular and connective tissue. The prostate produces and contains fluid that forms part of semen, the substance emitted during ejaculation as part of the male sexual response. This prostatic fluid is slightly alkaline, and milky or white in appearance. The alkalinity of semen helps neutralize the acidity of the vaginal tract, prolonging the lifespan of sperm. The prostatic fluid is expelled in the first part of ejaculate, together with most of the sperm, because of the action of smooth muscle tissue within the prostate. In comparison with the few spermatozoa expelled together with mainly seminal vesicular fluid, those in prostatic fluid have better motility, longer survival, and better protection of genetic material. Disorders of the prostate include enlargement, inflammation, infection, and cancer. The word prostate is derived from Ancient Greek prostátēs (προστάτης), meaning "one who stands before", "protector", "guardian", with the term originally used to describe the seminal vesicles.
==== Dextromethorphan ==== Dextromethorphan/bupropion, sold under the brand name Auvelity, is a combination medication approved by the US FDA in 2022 for the treatment of major depressive disorder (MDD) in adults. The formulation pairs dextromethorphan, an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion, a norepinephrine-dopamine reuptake inhibitor that also functions as a CYP2D6 enzyme inhibitor. Bupropion is included in the combination to slow the metabolism of dextromethorphan by inhibiting CYP2D6, thereby increasing its bioavailability and allowing dextromethorphan's potential antidepressant effects to be achieved. While the precise mechanism of action in treating depression is not fully understood, it is hypothesized that the medication works by modulating glutamate signaling and influencing other neurotransmitter systems.
Sources: en.wikipedia.org
== Controversies == Al-Fawzan has attracted criticism for a number of public statements and religious opinions. In 2003, he was quoted as saying that "slavery is a part of Islam" and that Muslims who deny this are ignorant and not scholars, comments that drew criticism for contradicting some contemporary interpretations of Islamic law. He has also described public demonstrations as haram, characterizing them as practices of non-Muslims that can lead to division and violence. In 2010, he called for a boycott against Adil al-Kalbani, who had stated that music was not haram (forbidden in Islam). The campaign was a fiasco, as the mosque was overcrowded during Adil al-Kalbani's next sermon. In 2011, opposing the Saudi Ministry of Justice's proposal to set a minimum age for girls' marriage, he reportedly issued a legal opinion authorizing fathers to marry off their daughters "even if they are still in the cradle". In 2014, Saleh al-Fawzan denied reports that he issued a fatwa banning open buffets, clarifying on his website that he had only commented that food of unspecified quantity should not be sold without specification. His statement addressed restaurants where customers pay a fixed price for unspecified portions. In 2015, he was quoted as saying that “Muslims must set aside games and frivolity and take up God’s work. They must not waste their time following games and frivolity, especially not during the blessed month of Ramadan. This is true for Muslims in general, and the younger generation in particular...
=== Differential diagnosis === 6-phosphogluconate dehydrogenase (6PGD) deficiency has similar symptoms and is often mistaken for G6PD deficiency, as the affected enzyme is within the same pathway; however, these diseases are not linked and can be found within the same person.
Highly popular Fast Forward holds influence over the other foster children, introducing them to drugs and pressuring them to give him money. Demon's mom, now pregnant, overdoses on oxyContin for the second time and dies. Demon returns for the funeral and spends Christmas with the Peggots, joining them on another trip to Knoxville. June has decided to move back to Lee County due to her colleagues in Knoxville demeaning her for being a 'redneck'. Demon begs the Peggots to adopt him, but they apologize and tell him their old age makes it impossible. A heartbroken Demon leaves Creaky Farms and is sent to stay with another neglectful foster family, the McCobbs, where he largely goes hungry and is made to feel like a financial burden. He is able to save some money by working for Mr. Ghali, a Dalit immigrant from India, who runs a garbage disposal operation (and implied meth lab) out of a gas station. Demon, now in fifth grade, remains neglected at home and is mocked at school for his unkempt appearance and bad smell. The McCobbs are forced to move due to financial issues. Demon runs away to avoid another foster placement. Neglected and hungry, Demon decides to hitchhike to Murder Valley, Tennessee, to find his paternal grandmother. He finds his grandmother Betsy Woodall, a hardy old woman who lives with her disabled brother Dick. Betsy contacts Coach Winfield, the coach of the Lee High Generals, who takes Demon in. Demon moves to Coach's mansion where he meets his daughter Agnes (nicknamed Angus after a misunderstanding) and a young man named U-Haul who assists Coach.
Manipulation of CpG-S and CpG-N sequences in the plasmid backbone of DNA vaccines can ensure the success of the immune response to the encoded antigen and drive the immune response toward a TH1 phenotype. This is useful if a pathogen requires a TH response for protection. CpG-S sequences have also been used as external adjuvants for both DNA and recombinant protein vaccination with variable success rates. Other organisms with hypomethylated CpG motifs have demonstrated the stimulation of polyclonal B-cell expansion. The mechanism behind this may be more complicated than simple methylation – hypomethylated murine DNA has not been found to mount an immune response. Most of the evidence for immunostimulatory CpG sequences comes from murine studies. Extrapolation of this data to other species requires caution – individual species may require different flanking sequences, as binding specificities of scavenger receptors vary across species. Additionally, species such as ruminants may be insensitive to immunostimulatory sequences due to their large gastrointestinal load.
Lysine (symbol Lys or K; also L-lysine) is an α-amino acid that is a precursor to many proteins. Lysine contains an α-amino group (which is in the protonated −NH+3 form when the lysine is dissolved in water at physiological pH), an α-carboxylic acid group (which is in the deprotonated −COO− form when the lysine is dissolved in water at physiological pH), and a side chain (CH2)4NH2 (which is partially protonated when the lysine is dissolved in water at physiological pH), and so it is classified as a basic, charged (in water at physiological pH), aliphatic amino acid. It is encoded by the codons AAA and AAG. Like almost all other amino acids, the α-carbon is chiral and lysine may refer to either enantiomer or a racemic mixture of both. For the purpose of this article, lysine will refer to the biologically active enantiomer L-lysine, where the α-carbon is in the S configuration. The human body cannot synthesize lysine. It is essential in humans and must therefore be obtained from the diet. In organisms that synthesize lysine, two main biosynthetic pathways exist, the diaminopimelate and α-aminoadipate pathways, which employ distinct enzymes and substrates and are found in diverse organisms. Lysine catabolism occurs through one of several pathways, the most common of which is the saccharopine pathway. Lysine plays several roles in humans, most importantly proteinogenesis, but also in the crosslinking of collagen polypeptides, uptake of essential mineral nutrients, and in the production of carnitine, which is key in fatty acid metabolism.
Sources: en.wikipedia.org
==== United States of America ==== The U.S. Drug Enforcement Administration issued a temporary order for the classification of desmetramadol in schedule 1 of the Controlled Substances Act for the period of August 12, 2026 through August 12, 2028.
Lisdexamphetamine was developed by Robert Oberlender at New River Pharmaceuticals, under the name NRP104, before being bought by Takeda Pharmaceuticals through its acquisition of Shire Pharmaceuticals, prior to market release. It was developed to create a longer-lasting and less-easily abused version of dextroamphetamine, as the requirement of conversion into dextroamphetamine via enzymes in the red blood cells delays its onset of action, regardless of the route of administration. In February 2007, the US Food and Drug Administration (FDA) approved lisdexamphetamine for the treatment of ADHD. In August 2009, Health Canada approved the marketing of lisdexamphetamine for prescription use. In January 2015, lisdexamphetamine was approved by the FDA for the treatment of binge eating disorder in adults. The FDA gave tentative approval to generic formulations of lisdexamphetamine in 2015. The expiration date for patent protection of lisdexamphetamine in the US was 24 February 2023. The Canadian patent expired 20 years from the filing date of 1 June 2004. Production quotas for 2016 in the United States were 29,750 kg.
== In history == Coronary occlusion was first discussed in 1910 by Sir William Osler who discussed coronary occlusion during the Lumleian Lectures. In 1912, James Herrick published an article in JAMA documenting his findings on coronary occlusion in animals. According to Robert K. Massie's Nicholas and Alexandra: The Fall of the Romanov Dynasty, Tsar Nicholas II may have suffered a coronary occlusion right before he was toppled from his throne during the Russian Revolution in 1917. Coroners cited a coronary occlusion as the cause of death for Montgomery Clift.
Trazodone is used at low doses in the range of 50 to 150 mg/day for insomnia. Higher doses of 200 to 600 mg/day have also been studied. The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommended against the use of trazodone in the treatment of insomnia due to inadequate evidence and due to harms potentially outweighing benefits.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.